EDEmily A. Dangelmaier

Emily A. Dangelmaier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emily A. Dangelmaier has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Ashish Lal

    Regulatory RNAs and Cancer Section, Genetics Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH)

    2 shared publications
  • Nadya Dimitrova

    Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06511, USA

    2 shared publications
  • Sigrid Nachtergaele

    Department of Molecular, Cellular, and Developmental Biology, Yale University , New Haven, CT 06511

    2 shared publications
  • Aaron Schetter

    Molecular Genetics and Carcinogenesis Section, Laboratory of Human Carcinogenesis, CCR, NCI, NIH, Bethesda, United States

    1 shared publication
  • Ana I Robles

    Molecular Genetics and Carcinogenesis Section, Laboratory of Human Carcinogenesis, CCR, NCI, NIH, Bethesda, United States

    1 shared publication
  • BinWu Tang

    Laboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, United States

    1 shared publication

Latest Publications

  • Open Access

    N 6-methyladenosine promotes temozolomide resistance through mRNA stabilization in glioblastoma cells

    by Emily A Dangelmaier, Dorthy Fang, Isabel P Hardy, Kyal Sin Htet, Nicole S Harry, Renee Pascoe, Je Won Yang, Clara D Wang, Sigrid Nachtergaele

    N 6-methyladenosine (m6A) regulates nearly every aspect of messenger RNA (mRNA) processing and function, impacting downstream gene expression programs. Changes in m6A have been implicated in many different types of cancer, and inhibition of m6A installation is emerging as a cancer therapeutic strategy. However, chemoresistance remains a significant clinical challenge in the treatment of glioblastoma (GBM). We established GBM cell culture models of acquired temozolomide (TMZ) resistance, analyzed the role of m6A in controlling resistance-associated pathways, and assessed the effects of METTL3 inhibition. We show that m6A stabilizes key genes and pathways promoting TMZ resistance, and that METTL3 inhibition can reverse this and restore TMZ sensitivity. These findings highlight that TMZ resistance can occur independent of a glioma stem cell population and that changes in m6A need not be driven by changes in METTL3 expression. Collectively, our results suggest that genes associated with TMZ resistance are stabilized by m6A methylation even as the majority of the transcriptome remains subject to m6A-mediated mRNA decay. Moreover, these data highlight METTL3 inhibition as a promising therapeutic approach to overcoming TMZ resistance in GBM.

  • Open Access

    Cell cycle–dependent translation-mediated turnover of the long noncoding RNA Malat1

    by Leah M. Plasek-Hegde, Yeolhoe Kim, Rahul V. Gupta, Emily A. Dangelmaier, Sigrid Nachtergaele, Nadya Dimitrova

    Increased abundance of the nuclear long noncoding RNA (lncRNA) Malat1 drives metastatic progression and is a strong predictor of poor patient prognosis. Although the mechanism that stabilizes Malat1 through processing of its 3′ terminus is well-characterized, the pathways governing its turnover remain poorly understood. Here, we show that upon exit from mitosis, Malat1 localizes to the cytoplasm, where it is degraded during early G1, resetting its abundance at the start of each cell cycle. Mechanistically, we demonstrate that Malat1 turnover is mediated by a translation- and Smg1-dependent decay pathway and triggered by redundant elements. Importantly, failure to reset Malat1 levels in early G1, due to decay inhibition or in the absence of progression through mitosis, results in Malat1 accumulation. These findings uncover a cell cycle–dependent mechanism that harnesses the translation machinery to regulate Malat1 abundance and identify cancer cell dormancy as a potential mechanism underlying the widespread overexpression of Malat1 in cancer.

  • Open Access

    Activation of Pvt1b isoform contributes to local Pvt1 abundance to repress Myc during stress

    by Qiao Li, Christiane E. Olivero, Erin Floyd, Jane Ding, Emily Dangelmaier, James Knight, Nadya Dimitrova

    Many long noncoding RNA (lncRNA) loci harbor multiple alternative isoforms. It is not known whether isoform-specific sequence elements enable distinct functions. Previous work identified two alternative transcription start site (TSS) isoforms in the Pvt1 lncRNA locus - the constitutively expressed Pvt1a and the stress-induced Pvt1b. While the function of Pvt1a is not known, the p53-regulated Pvt1b was shown to act locally to repress the transcription of the neighboring Myc proto-oncogene in response to genotoxic and oncogenic stress. Here, we investigated whether Pvt1b contains isoform-specific repressive sequence elements. Our results revealed that Pvt1b contributes to but is not required for Myc repression. Using in vivo and in vitro models of genotoxic and oncogenic stress, we observed that Pvt1a compensates for Pvt1b loss, resulting in Pvt1b deficiency having a moderate effect on Myc regulation, stress response, and tumor suppression. Long-read sequencing exposed a diversity of stress-induced Pvt1a and Pvt1b isoforms, further arguing against a specialized role for Pvt1b. We propose that p53-induced increase in total Pvt1 abundance, and not isoform-specific activation, represses Myc during stress.


  • Experimental Validation of the Noncoding Potential for lncRNAs

    by Emily A. Dangelmaier, Ashish Lal

    In recent years, long noncoding RNAs (lncRNAs) have been increasingly recognized as critical regulators of a broad spectrum of cellular processes. Recent advancements in proteomic technologies have uncovered that an abundance of noncoding genes, including lncRNAs, have been misannotated and in reality encode proteins. This revelation underscores the need to accurately determine the coding potential of lncRNAs prior to assessment of their functional mechanisms. Here, we detail numerous experimental techniques useful in the determination of lncRNA coding potential. Several of these methods are doubly useful in that they may also be employed in studying the function of a lncRNA, be it via an RNA, protein, or both.


  • Open Access

    A small protein encoded by a putative lncRNA regulates apoptosis and tumorigenicity in human colorectal cancer cells

    by Xiao Ling Li, Lőrinc Pongor, Wei Tang, Sudipto Das, Bruna R Muys, Matthew F Jones, Sarah B Lazar, Emily A Dangelmaier, Corrine Cr Hartford, Ioannis Grammatikakis, et al.

    Long noncoding RNAs (lncRNAs) are often associated with polysomes, indicating coding potential. However, only a handful of endogenous proteins encoded by putative lncRNAs have been identified and assigned a function. Here, we report the discovery of a putative gastrointestinal-tract-specific lncRNA (LINC00675) that is regulated by the pioneer transcription factor FOXA1 and encodes a conserved small protein of 79 amino acids which we termed FORCP (FOXA1-Regulated Conserved Small Protein). FORCP transcript is undetectable in most cell types but is abundant in well-differentiated colorectal cancer (CRC) cells where it functions to inhibit proliferation, clonogenicity, and tumorigenesis. The epitope-tagged and endogenous FORCP protein predominantly localizes to the endoplasmic reticulum (ER). In response to ER stress, FORCP depletion results in decreased apoptosis. Our findings on the initial characterization of FORCP demonstrate that FORCP is a novel, conserved small protein encoded by a mis-annotated lncRNA that regulates apoptosis and tumorigenicity in well-differentiated CRC cells.